Concepedia

Sequential Dual Checkpoint Blockade

Sequential Dual Checkpoint Blockade is a therapeutic strategy in immuno-oncology that involves the non-overlapping, temporally staged administration of two distinct immune checkpoint inhibitors to sequentially target different inhibitory pathways in the cancer immunity cycle, thereby aiming to enhance antitumor immune responses while managing toxicity.

7

Publications

764

Citations

105

Authors

80

Institutions

Publications per year

2017–2026

6

Parents

Publications

7

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan et al. · The Lancet Oncology · 2016 · 335 citations

, , +16

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research · 2021 · 125 citations · Full text

, , +17

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Yana G. Najjar, Kristina Navrazhina, Fei Ding et al. · Journal for ImmunoTherapy of Cancer · 2020 · 124 citations · Full text

, , +14

Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy

Mauricio Burotto, Juan G. Gormaz, Suraj Samtani et al. · Seminars in Oncology · 2018 · 75 citations

, , +16

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Jaume Capdevila, Jorge Hernando, Àlex Teulé et al. · Nature Communications · 2023 · 53 citations · Full text

, , +17

1–5 of 7

Authors

105

  1. IP
    Igor Puzanov

    Vanderbilt University Medical Center, United States

    1 publications · 124 citations

    1

    h-index

  2. YL
    Yuan Liu

    Emory University, United States

    1 publications · 13 citations

    1

    h-index

  3. AC
    Akansha Chowdhary

    Northwestern University, United States

    1 publications · 124 citations

    1

    h-index

  4. RG
    Rocio García‐Carbonero

    Hospital Universitario 12 De Octubre, Spain

    1 publications · 53 citations

    1

    h-index

  5. LA
    Leslie A. Fecher

    University of Michigan, United States

    1 publications · 335 citations

    1

    h-index

1–5 of 105

Institutions

80

  1. Indiana University – Purdue University Indianapolis

    Indianapolis, United States

    2 h-index

    4 publications

    920 citations

  2. Indiana University Health

    Indianapolis, United States

    2 h-index

    4 publications

    920 citations

  3. Massachusetts General Hospital

    Boston, United States

    2 h-index

    4 publications

    918 citations

  4. NYU Langone Health

    New York, United States

    2 h-index

    2 publications

    460 citations

  5. Dana-Farber Cancer Institute

    Boston, United States

    2 h-index

    2 publications

    460 citations

  6. University of Michigan

    Ann Arbor, United States

    2 h-index

    3 publications

    585 citations

  7. Moffitt Cancer Center

    Tampa, United States

    2 h-index

    3 publications

    794 citations

  8. Midwestern University

    Downers Grove, United States

    1 h-index

    1 publications

    125 citations

1–8 of 80

Venues

  1. Seminars in Oncology

    1 publications · 75 citations

    1

    h-index

  2. Clinical Cancer Research

    1 publications · 125 citations

    1

    h-index

  3. Journal for ImmunoTherapy of Cancer

    JITC · 1 publications · 124 citations

    1

    h-index

  4. Nature Communications

    1 publications · 53 citations

    1

    h-index

  5. Investigational New Drugs

    1 publications · 13 citations

    1

    h-index

1–5